Publications

Publications

Filter Results: (20) Arrow Down

Show Results For

Page 1 of 20 Results
Sort by

Are you looking for?

→Search All HBS Web
  • November 2016
  • Case

QuintilesIMS: Biosimilar Marketing in England

By: John A. Quelch and Emily C. Boudreau
QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details
Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England
Related
  • June 2017
  • Teaching Note

QuintilesIMS: Biosimilar Marketing in England

By: John A. Quelch and Emily C. Boudreau
Teaching Note for HBS No. 517-054. View Details
Related
  • Other Article

Biosimilars and Follow-On Products: The Authors Reply

By: Ariel Dora Stern and Mark R. Trusheim
Related
  • Article

Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users

By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details
Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States
Related
  • June 9, 2023
  • Article

A Radical Treatment for Insulin Pricing

By: Leemore S. Dafny
In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a... View Details
Keywords: Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States
Related
  • August 2018
  • Article

The Impact of the Entry of Biosimilars: Evidence from Europe

By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby... View Details
Keywords: Health Care; Biosimilars; Biologics; Pharmaceutical Competition; Healthcare Spending; Innovation; Health Care and Treatment; Spending; Market Entry and Exit; Competition; Innovation and Invention; Pharmaceutical Industry; United States; Europe
Related
  • January 2014 (Revised June 2015)
  • Teaching Note

Amgen Inc: Pursuing Innovation and Imitation? (A), (B)

By: Ian Mackenzie
Keywords: Strategic Change; Biosimilars; Medical Biotechnology; Emerging Markets; Industry Structure; Uncertainty; Strategy Development; Implementation; Corporate Strategy; Pharmaceutical Industry; Biotechnology Industry; United States
Related
  • 26 Jul 2016
  • Working Paper Summaries

The Impact of the Entry of Biosimilars: Evidence from Europe

Keywords: by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern; Health; Biotechnology; Pharmaceutical
  • 12 Jul 2016
  • First Look

July 12, 2016

States since 2015. Europe has had biosimilar entry since 2006. This paper considers how competition from biosimilars may impact the U.S. biosimilar market by examining data... View Details
Keywords: Sean Silverthorne
  • May 2016
  • Case

AbbVie

By: Kevin Schulman, Laura Little, Samyukta Mullangi and Stephen Schleicher
This case focuses on the impact of a novel regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars... View Details
Keywords: Pharmaceutical Company; M＆A Valuation; AbbVie; Health Care; Health Care and Treatment; Pharmaceutical Industry; Health Industry; United States
Related
  • January 2014
  • Supplement

Amgen Inc.: Pursuing Innovation and Imitation? (B)

By: Ian Mackenzie
The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details
Keywords: Corporate Strategy; Pharmaceutical Industry; Biotechnology Industry; United States
Related
  • February 2016 (Revised February 2017)
  • Case

Alvogen

By: Daniel Isenberg and William Kerr
Alvogen is a young Icelandic generic pharmaceutical company, whose CEO believes that his global strategy will give them an edge in this competitive industry.
Robert Wessman, Alvogen’s CEO, was also previously the CEO of Actavis, another Icelandic generics... View Details
Keywords: Pharmaceutical Companies; Generic Drugs; Entrepreneurship; Globalization; Risk and Uncertainty; Pharmaceutical Industry; Iceland
Related
  • January 2014 (Revised June 2015)
  • Case

Amgen Inc.: Pursuing Innovation and Imitation? (A)

By: Ian W. Mackenzie
Set in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification:... View Details
Keywords: Corporate Strategy; Pharmaceutical Industry; Biotechnology Industry; United States
Related
  • 21 Aug 2018
  • First Look

New Research and Ideas, August 21, 2018

growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby largely... View Details
Keywords: Dina Gerdeman
  • 09 Aug 2016
  • First Look

August 9, 2016

drugs that have been shown to be therapeutically equivalent to an already approved original biologic drug—have only been approved in the United States since 2015. Europe has had biosimilar entry since 2006. This paper considers how... View Details
Keywords: Sean Silverthorne
  • 01 Aug 2017
  • First Look

First Look at New Research and Ideas, August 1

approved in the United States only since 2015. Europe, however, has had biosimilar entry since 2006; we consider how competition from biosimilars might impact the U.S. View Details
Keywords: Sean Silverthorne
  • 18 Apr 2018
  • First Look

First Look at New Research and Ideas, April 18, 2018

product upon entry, however only a few biosimilars have been approved in the U.S. since 2015, thereby largely preserving biologics from competition. We analyze European markets, which have had biosimilar... View Details
Keywords: Sean Silverthorne
  • 07 Jul 2015
  • First Look

First Look: July 7, 2015

biosimilars (BS), which are essentially "me-too" products. There appear to be sound reasons to explore this related diversification: innovation is getting harder, regulators are intent on encouraging BS, and Amgen needs renewed... View Details
Keywords: Sean Silverthorne
  • 06 Jun 2017
  • First Look

First Look at New Research and Ideas: June 6, 2017

regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging View Details
Keywords: Sean Silverthorne
  • 14 Mar 2017
  • First Look

First Look at New Research, March 14

Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/317023-PDF-ENG Harvard Business School Case 517-054 QuintilesIMS: Biosimilars Marketing in England QuintilesIMS was a leading healthcare consulting firm best known for its data... View Details
Keywords: Sean Silverthorne

Are you looking for?

→Search All HBS Web